Seeding and scaling Ontario’s premiere entrepreneurial ventures for patients and the economy.
Our investments have resulted in significant partnerships, clinical trials, job creation and leveraged financing for the province.
Keep up to date on our investments and business developments in recent news stories and summaries.
August 2, 2023 – FACIT and T-CAIREM announce partnership to commercialize medical artificial intelligence (AI) innovations. The partners intend to harness both T-CAIREM’s innovative translational research in AI and FACIT’s unique commercialization-venture model to build the next generation of Ontario biotechnology companies. The joint mission will accelerate the benefits of AI research to support patients…
July 24, 2023 – The U.S. FDA announced the approval of quizartinib, an important new therapy for patients with leukemia. This global effort to impact patients in need is to be celebrated while recognizing the contributions from across the Canadian health R&D ecosystem to reach this significant milestone that will now make a difference for…
July 21, 2023 – FACIT congratulates Turnstone Biologics on the announcement of their upsized initial public offering (IPO) and debut on the Nasdaq market. Read More from FACIT founded Turnstone Biologics debuts on Nasdaq market
We were established by the Ontario Institute for Cancer Research (OICR) to support commercialization, technology transfer, and development activities. OICR conducts and enables world-class cancer research, filling a critical role as a pan-provincial connector of oncology researchers, resources and cancer innovation development. Together with OICR, we drive a shared vision to attract more R&D investment in Ontario and help the best oncology innovations reach the market and save lives.
FACIT is funded in part by the Government of Ontario through OICR